Abstract:Major depression is a common and severe psychiatric disorder with a highly polygenic genetic architecture. Genome-wide association studies have successfully identified multiple independent genetic loci that harbour variants associated with major depression, but the exact causal genes and biological mechanisms are largely unknown. Tissue-specific network approaches may identify molecular mechanisms underlying major depression and provide a biological substrate for integrative analyses. We provide a framework for the identification of individual risk genes and gene co-expression networks using genome-wide association summary statistics and gene expression information across multiple human brain tissues and whole blood. We developed a novel gene-based method called eMAGMA that leverages tissue-specific eQTL information to identify 99 biologically plausible risk genes associated with major depression, of which 58 are novel. Among these novel associations is Complement Factor 4A (C4A), recently implicated in schizophrenia through its role in synaptic pruning during postnatal development. Major depression risk genes were enriched in gene co-expression modules in multiple brain tissues and the implicated gene modules contained genes involved in synaptic signalling, neuronal development, and cell transport pathways. Modules enriched with major depression signals were strongly preserved across brain tissues, but were weakly preserved in whole blood, highlighting the importance of using disease-relevant tissues in genetic studies of psychiatric traits. We identified tissue-specific genes and gene co-expression networks associated with major depression. Our novel analytical framework can be used to gain fundamental insights into the functioning of the nervous system in major depression and other brain-related traits.Although genome-wide association studies have identified genetic risk variants associated with major depression, our understanding of the mechanisms through which they influence disease susceptibility remains largely unknown. Genetic risk variants are highly enriched in non-coding regions of the genome and affect gene expression. Genes are co-expressed and regulate the activity of one another to form highly organized networks. In this study, we generate tissue-specific gene co-expression networks, each containing groups of functionally related genes or "modules", to delineate gene co-expression and thereby facilitate the identification of gene processes in major depression. We developed and applied a novel research methodology (called "eMAGMA") which integrates genetic and transcriptomic information in a tissue-specific analysis to identify risk genes and test for their enrichment in gene co-expression modules. Using this novel approach, we identified gene modules in multiple tissues that are both enriched with major depression genetic association signals and biologically meaningful pathways. We also show the disease implicated gene modules are strongly preserved across brain regions, but not in whole blood, suggesting unique patterns of gene co-expression within the two tissue types. Our novel analytical framework provides important insights into the functional genetics major depression and can be applied to other neuropsychiatric disorders.

T-SEM of 11 Major Psychiatric Disorders: Identification of Gene Expression Patterns for Cross-Disorder Risk and Drug Repurposing

Transcriptome-Wide Structural Equation Modeling of 13 Major Psychiatric Disorders for Cross-Disorder Risk and Drug Repurposing

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders

The multivariate genetic architecture of psychiatric and insulin resistance multimorbidity

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and Compounds

Combining Transdiagnostic and Disorder-Level GWAS Enhances Precision of Psychiatric Genetic Risk Profiles in a Multi-Ancestry Sample

Examining the Genetic Links between Clusters of Immune-mediated Diseases and Psychiatric Disorders

Network-based drug repurposing for psychiatric disorders using single-cell genomics

Transcriptome Profiling of Dysregulated GPCRs Reveals Overlapping Patterns across Psychiatric Disorders and Age-Disease Interactions

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.

Cross-disorder Genomewide Analysis of Schizophrenia, Bipolar Disorder, and Depression.

Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms

Application of GWAS summary data and drug-induced gene expression profiles of neural progenitor cells in psychiatric drug prioritization analysis

Genome wide meta-analysis identifies genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders

A Comprehensive Gene-Centric Pleiotropic Association Analysis for 14 Psychiatric Disorders with GWAS Summary Statistics

Spatial Expression Pattern of ZNF391 Gene in the Brains of Patients with Schizophrenia, Bipolar Disorders or Major Depressive Disorder Identifies New Cross-Disorder Biotypes: A Trans-Diagnostic, Top-Down Approach

Genome-Wide Mendelian Randomization Reveals Genetically-Supported Drug Targets for Psychiatric Disorders

Shared Molecular Neuropathology Across Major Psychiatric Disorders Parallels Polygenic Overlap

A gene co-expression network-based analysis of multiple brain tissues reveals novel genes and molecular pathways underlying major depression

Leveraging pleiotropy for the improved treatment of psychiatric disorders

Shared genetic architecture of psychiatric disorders and hemorrhoidal disease: a large-scale genome-wide cross-trait analysis